Covestor
ELVN icon

Covestor’s Enliven Therapeutics ELVN Stock Holding History

Covestor’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-15
Closed -$1K – 2481
2026
Q2 		$1K Buy
15
+9
+150% +$382 ﹤0.01% 2129
2026
Q1 		$0 Hold
6
– – ﹤0.01% 2380
2025
Q4 		$0 Sell
6
-11
-65% -$219 ﹤0.01% 2368
2025
Q3 		$0 Buy
17
+11
+183% +$222 ﹤0.01% 2392
2025
Q2 		$0 Hold
6
– – ﹤0.01% 2333
2025
Q1 		$0 Hold
6
– – ﹤0.01% 2348
2024
Q4 		$0 Hold
6
– – ﹤0.01% 2351
2024
Q3 		$0 Hold
6
– – ﹤0.01% 2341
2024
Q2 		$0 Buy
6
+5
+500% +$105 ﹤0.01% 2352
2024
Q1 		$0 Hold
1
– – ﹤0.01% 2352
2023
Q4 		$0 Hold
1
– – ﹤0.01% 2266
2023
Q3 		$0 Hold
1
– – ﹤0.01% 2242
2023
Q2 		$0 Buy
+1
New +$20 ﹤0.01% 2253

Other funds holding ELVN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Covestor's ELVN Position: Q3 2026 in Review

Covestor sold out of Enliven Therapeutics (ELVN) in Q3 2026, closing a stake of 15 shares — an estimated $1K sold.

Covestor first reported a position in ELVN in Q2 2023 and held it in 13 quarters. The position peaked at $1K in Q2 2026. 54 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • Covestor reported no remaining Enliven Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Covestor sold 15 Enliven Therapeutics shares in Q3 2026, an estimated $1K.
  • Covestor first reported a position in Enliven Therapeutics in Q2 2023 and held it in 13 quarters.
  • Covestor's Enliven Therapeutics position peaked at $1K in Q2 2026.
  • 54 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on Covestor's 13F filing for Q3 2026, filed 30 Oct 2026.